Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Gala-diner schreef op 3 juni 2019 16:20 :
[...]
Nou ja, oud...
Dat valt wel mee dacht ik, ik zag alleen een link en daarom heb ik het geplaatst.Ik zie het als een bevestiging van mijn visie op Probiodrug dat er recentelijk 2 nieuwe grootaandeelhouders zijn bij gekomen.
Per saldo zijn er niet meer aandelen in handen gekomen van grote beleggers, dankzij de grote verkoper.
DeZwarteRidder schreef op 3 juni 2019 17:21 :
[...]
Per saldo zijn er niet meer aandelen in handen gekomen van grote beleggers, dankzij de grote verkoper.
Nu ik jouw secretaris heb gezien, ongetwijfeld weer een broodje-aap-verhaal. Lol
fd183 schreef op 3 juni 2019 18:40 :
[...]
Nu ik jouw secretaris heb gezien, ongetwijfeld weer een broodje-aap-verhaal. Lol
Ik heb die aap ontslagen wegens geknoei met de boeken en heb een nieuwe secretaris:
Da's geen secretaris, maar een na-aper. Lol
DeZwarteRidder schreef op 3 juni 2019 19:10 :
[...]
Ik heb die aap ontslagen wegens geknoei met de boeken en heb een nieuwe secretaris:je bent op tv bij de zwakste schakel en je ligt er wederom weer uit
Bridget zegt u bent de zwakste schakel u kunt gaan
Je bakt er niks van man je hebt alles fout Zit ik weer mn tijd te verdoen om naar je onzin te luisteren
neet schreef op 3 juni 2019 22:44 :
Je bakt er niks van man je hebt alles fout
Zit ik weer mn tijd te verdoen om naar je onzin te luisteren
De beste man leeft in een duistere fantasiewereld, daar zijn wel pilletje voor. Maar heeft het zelf niet in de gaten. Het is ongetwijfeld een eenzaam persoon. Best sneu eigenlijk. Zijn 'secretaris' heeft nu met zijn Pinkeltjes-boeken geknoeid las ik.. Hopeloos geval. Hij zit er inderdaad bijna altijd naast met zijn 'visie' op verschillende aandelen. Als ik een keer tijd en zin hebczal ik eens een mooi overzicht maken van zijn missers, worst wel paginavullend.
Gala-diner schreef op 3 juni 2019 23:05 :
[...]
De beste man leeft in een duistere fantasiewereld, daar zijn wel pilletje voor.
Maar heeft het zelf niet in de gaten.
Het is ongetwijfeld een eenzaam persoon.
Best sneu eigenlijk.
Zijn 'secretaris' heeft nu met zijn Pinkeltjes-boeken geknoeid las ik..
Hopeloos geval.
Hij zit er inderdaad bijna altijd naast met zijn 'visie' op verschillende aandelen.
Als ik een keer tijd en zin hebczal ik eens een mooi overzicht maken van zijn missers, worst wel paginavullend.
dat wordt een dag taak Gala
neet schreef op 3 juni 2019 22:42 :
[...]
Je mag mijn teksten niet veranderen dmv een quote.
DeZwarteRidder schreef op 4 juni 2019 15:23 :
[...]
Je mag mijn teksten niet veranderen dmv een quote.
Waarom niet? Hij aapt jou alleen maar na, heeft ie van jouw secretaris geleerd.
June 2019 3 – 6: BIO International Convention, Philadelphia, USA Probiodrug aanwezig.
Gala-diner schreef op 5 juni 2019 08:15 :
June 2019
3 – 6: BIO International Convention, Philadelphia, USA
Probiodrug aanwezig.
BIO 2019 - June 3-6 - Philadelphia, PA Join us in Philadelphia, PA, June 3-6, 2019 as more than 16,000 attendees from around the globe gather for unparalleled partnering, education, networking, and to see all that tri-state area has to offer. The region's vast array of leading universities and research institutions fosters a collaborative environment. The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 67 countries.
Lijkt mij een geweldige performster op het galadiner (na sluitingstijd 17 juni 2019).www.youtube.com/watch?v=6WwMg20XYVs
Go4profit schreef op 6 juni 2019 17:36 :
Lijkt mij een geweldige performster op het galadiner (na sluitingstijd 17 juni 2019).
www.youtube.com/watch?v=6WwMg20XYVs Karaoke....???
fd183 schreef op 7 juni 2019 07:19 :
Met dit op het menu?
www.hollandandbarrett.nl/shop/product... www.bollingershop.nl/bollinger-specia... Dacht eerder hier aan :-)
Probiodrug AG becomes Vivoryon Therapeutics AG DGAP-News: Vivoryon Therapeutics AG / Key word(s): Corporate Action 12.06.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Probiodrug AG becomes Vivoryon Therapeutics AG Healthy Aging - Pioneering Innovation HALLE (SAALE), Germany, 12 June 2019 - Probiodrug AG (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), focusing on the discovery and development of drugs acting on enzymes which modulate the activity of cellular signalling pathways connected to human diseases, announced today that with entry into the commercial register Stendal the Company has now officially changed its name to Vivoryon Therapeutics AG as of June 11, 2019. Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics AG, explained that the new name is representative of the evolving commitment of the Company to promote "Healthy-Aging - Pioneering Innovation", adding, "Vivoryon, composed of 'Vivid Memory On', expresses our strong commitment to develop a transformational therapeutic option for patients with Alzheimer's Disease (AD) against the backdrop of multiple late stage industry disappointments. With our proprietary Glutaminyl cyclase (QC) inhibition platform we are technology leaders in this field which has also opened up new opportunities to bring scientific excellence for the benefit of patients to other indications, as we currently see in immuno-oncology." The name change is a result of a shareholder resolution passed at the Company's Annual General Meeting held on May 29, 2019. In the past year, Vivoryon Therapeutics, has mastered important steps for a successful future. With new management, the Company is well positioned to tackle the next developmental stages of its lead candidate PQ912, a first-in-class, highly specific and potent inhibitor of Glutaminyl-peptide cyclotransferase protein (QPCT), which is highly relevant in the brain and the AD-process, and its isoenzyme, the Glutaminyl-peptide cyclotransferase-like protein (QPCTL), which is relevant in immuno-oncological signaling processes. Vivoryon Therapeutics will continue to focus on therapeutic solutions for AD, a complex neurological disorder, which is the most common form of dementia. There is currently no cure for Alzheimer's and approved medication only treat some symptoms of the disease. Vivoryon's lead molecule PQ912, which inhibits QPCT as the crucial enzyme for the generation of highly neurotoxic pyroglutamate species of Abeta in the brain, will be investigated in two clinical Phase 2b trials in Europe and the U.S. for the treatment of AD. The Company, is also exploring options to expand their research into the field of immuno-oncology, the study and development of treatments that take advantage of the body's immune system to fight cancer. Glutaminyl-peptide cyclotransferase-like protein (QPCTL), a posttranslational modifying enzyme that is responsible for the pyroglutamate formation on crucial signaling proteins in oncological immune responses, has recently been identified as a potential oncological target. Inhibitors of QPCTL, like PQ912 and other small molecule compounds protected under Vivoryon's patents have been shown to silence the checkpoint signal from the CD47/SIRP alpha axis between cancer cells and cells of the innate immune system, and thus are offering a novel strategy to augment the efficacy of various antibody therapies in cancer. As such, the name Vivoryon Therapeutics will highlight the new positioning of the Company's key strengths as a leader in the development of post translational modifying enzymes. ### For more information, please contact: Vivoryon Therapeutics AG Dr. Ulrich Dauer, CEO Email: contact@vivoryon.com MC Services AG Anne Hennecke, Susanne Kutter Tel: +49 (0) 211 529 252 27 Email: vivoryon@mc-services.eu Notes to Editors: About Vivoryon Therapeutics AG Headquartered in Halle (Saale), Germany, Vivoryon Therapeutics AG (Euronext Amsterdam: currently PBD, to be changed to VVY) is a clinical stage precision medicine company focused on bringing first-in-class therapies to patients suffering from age-related diseases. The company has a successful track record in bringing drugs targeted to post-translational modifying enzymes to the market. Current projects are focusing on the two isoenzymes of Glutaminyl cyclase, QPCT and QPCTL. QPCT is the crucial enzyme for the generation of highly neurotoxic pyroglutamate species of Abeta. Its inhibition by Vivoryon's lead molecule PQ912, has successfully completed a Phase 2a (SAPHIR) study and the Company has initiated a Phase 2b core program for the treatment of Alzheimer's disease (AD). Whereas QPCTL has been identified as a potential target in cancer therapy. Blocking the enzymatic function of QPTCL by small molecule inhibitors is a novel therapeutic approach to silence the CD47/SIRP alpha signal in cancer immunotherapy. Vivoryon has a unique and exceptionally strong patent position on QPCT and QPCTL inhibitors.www.vivoryon.com About PQ912 PQ912, is a first-in-class, highly specific and potent inhibitor of Glutaminyl-peptide cyclotransferase protein (QPCT), the enzyme that catalyzes the formation of highly neurotoxic pGlu species. PQ912 has shown therapeutic effects in AD animal models. A Phase 1 study in healthy young and elderly volunteers revealed a dose dependent exposure and showed good safety and tolerability up to the highest dose resulting in >90% target occupancy in the spinal fluid. In June 2017, Vivoryon announced promising top-line data of the Phase 2a SAPHIR trial of PQ912 and presented the study results at CTAD 2017. Results strongly support that pGlu species of Abeta are especially neurotoxic and correlate with AD disease progression. The SAPHIR study provides important guidance on how to move forward with the development of PQ912 as a disease-modifying drug for AD. Altogether, the results make the program highly attractive for further development; the company has initiated the preparation of a Phase 2b core program. About Alzheimer's disease Alzheimer's disease is a neurological disorder, which is the most common form of dementia. Today, 50 million people live with dementia worldwide, and this number is projected to triple to more than 152 million by 2050. Dementia also has a huge economic impact. Alzheimer's has an estimated, global societal cost of US$ 1 trillion, and it will become 2 trillion-dollar disease by 2030. (World Alzheimer Report 2018). Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a posttranslational modifying enzyme that is responsible for the pyroglutamate formation on CD47 a crucial receptor protein in the immune response to cancer. QPCTL is an isoenzyme of QPCT and can be inhibited by Vivoryon's lead candidate small molecule PQ912 and other compounds protected under Vivoryon's patents. Cancer immune checkpoint inhibitors Checkpoint inhibitor therapy is a novel kind of cancer immunotherapy. This therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system. QPCTL inhibitor therapy can silence inhibitory cancer checkpoints and thereby restore beneficial immune system functions
Probiodrug nu officieel Vivoryon Therapeutics Gepubliceerd op 12 jun 2019 om 07:15 | Views: 1.156 | Onderwerpen: biotechnologie Probiodrug 12:35 5,19 -0,09 (-1,70%) HALLE (AFN) - De in Amsterdam genoteerde Duitse biotechnoloog Probiodrug heeft zijn naam officieel gewijzigd in Vivoryon Therapeutics. Nadat eerder al aandeelhouders akkoord gingen met de aanpassing, is deze nu ook doorgevoerd in de registers van de Kamer van Koophandel. Vivoryon werkt aan een geneesmiddel tegen de ziekte van Alzheimer. De nieuwe naam is samengesteld uit 'Vivid Memory On'.
Inclusief aanstaande maandag zitten er 2 maanden op. De uitslag is 56% van de dagen ---- 4,90 of eronder en 44% boven de 4,90. De voorspelling van mij was dominant zwabberen onder de 4,90 in deze twee maanden maar ik matig mij aan dan zou het percentage onder de 4,90 boven de 80% moeten liggen. In die vergelijking heb ik het dus onjuist gezien echter de koers is bij 5,23 (momentopname) slechts >= 0,33 euro er boven dus zo ver is mijn schatting nou ook weer niet weg van mijn geschatte doel. De schatting van Gala-diner binnen 2 maanden ---- 15 euro is natuurlijk een sprookje gebleken en daar valt geen speld tussen te krijgen. Ik heb geen aandelen VT-AG (Probiodrug) en ben niet van plan VT-AG stukken aan te schaffen dus blijven posten is eigenlijk energie_verspilling. Ik neem bij deze dan ook afscheid van dit forum en wens een ieder succes !
Vantage - March 20, 2019 - Madeleine Armstrong Probiodrug wins a market cap-sized grant for Alzheimer’s trial Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912. White silhouette of head, as a jigaw puzzle with a piece missing, against black backgroud Raising money is nothing new for biotech companies. But in scoring a grant worth nearly as much as its market cap, Probiodrug has something to write home about. Investors sent the German company’s shares up as much as 36% today on news of a $15m award from the US NIH; yesterday the group was valued at €16m ($18m). Probiodrug might now finally be able to start a US phase IIb trial of its Alzheimer’s disease candidate PQ912, but it is not out of the woods just yet. The grant will not fully fund the study and, at last count, the group had just €5m in the bank. More money more problems Probiodrug’s chief executive, Ulrich Dauer, told Vantage that the company did not want to start the trial without having the funds to finish it, or at least get to a “reasonable point”. That reasonable point could be the end of a dose-escalation phase, he suggested. Probiodrug has not nailed down the exact design of the trial, but the current plan is to start with a PQ912 dose of 150mg, before upping this to 300mg, and then 600mg. The company would then pick the highest tolerated dose to take into the chronic part of the study. With this in mind, the chief exec said it was premature to speculate on the minimum amount of money Probiodrug would need to start the trial. Mr Dauer also would not disclose how much the $15m NIH grant might cover, and how much Probiodrug would have to fund itself, although he did admit that the company could be on the hook for a substantial amount. The study is slated to enrol around 460 patients in the US and Canada with mild cognitive impairment or mild dementia due to Alzheimer’s, who would receive PQ912 or placebo for 18 months. Phase II Alzheimer's disease trials typically cost around $23m, according to EvaluatePharma Vision, though as Probiodrug is talking about a larger phase IIb study, the final bill would probably be significantly higher. This makes the NIH funds start to look like a drop in the ocean, particularly when considering that Probiodrug also plans to start enrolling patients into a phase IIb European trial, Saphir 2, by the end of this year. Current funds are only expected to keep Probiodrug going until the third quarter of 2019. Searching for a partner The company therefore needs to find more cash, with partnering or an equity raise at the top of the agenda, the chief exec said. He maintained that there was still interest from potential collaborators, despite the mounting casualty list of Alzheimer’s projects, most recently Roche’s anti-beta amyloid antibody crenezumab. Although Probiodrug is also targeting amyloid, the company might benefit from taking a slightly different approach. PQ912 is a small-molecule inhibitor of glutaminyl cyclase, the enzyme that converts beta-amyloid into what the company calls the toxic pGlu-Abeta form. The most similar project in development is Lilly’s LY3002813, an antibody that binds directly to pGlu-Abeta. Notably, Lilly kept faith with this project when it cut back its Alzheimer’s pipeline last year, something Mr Dauer said he was pleased about because it validated Probiodrug’s strategy (Eli Lilly backs away from Bace but not from novel Alzheimer’s targets, 14 November 2018). Still, LY3002813, which had once been behind PQ912, is pushing ahead fast. LY3002813 is in a phase II trial, Trailblazer-Alz, which is due to complete next year, according to clinicaltrials.gov. The NIH money is a start, but Probiodrug needs more than $15m if it wants to keep going with PQ912, let alone keep up with a bigger rival. Niet vers van de pers maar er klinkt zacht muziek in door...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee